MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Primary demo aims ended up To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, when one of many explora... https://silass999grb2.governor-wiki.com/user